HSBC Initiates Coverage On bluebird bio with Buy Rating, Announces Price Target of $4.21
Portfolio Pulse from Benzinga Newsdesk
HSBC analyst Morten Herholdt has initiated coverage on bluebird bio (NASDAQ:BLUE) with a Buy rating and a price target of $4.21.
September 06, 2023 | 9:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HSBC has initiated coverage on bluebird bio with a Buy rating and a price target of $4.21, which could positively impact the stock's performance.
Analyst ratings and price targets can significantly influence a stock's performance. In this case, HSBC's Buy rating and price target for bluebird bio suggest a positive outlook for the stock, which could lead to an increase in its price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100